Protocol library
SingleNot ApprovedEarly HumanLow confidenceSourced

AOD-9604

A modified growth-hormone fragment investigated for obesity. Human development did not establish an authorised obesity treatment or a routine-use protocol.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Community-reported schedule

Community-reported · not a validated schedule

Community dose schedule

A community-provenance subcutaneous dose from an authenticated research forum, around 250-500 mcg once daily taken fasted. Forum reports only, not a validated or trial-verified schedule.

Evidence source
Reported maximum quantity
Low daily dose (forum)
Choose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.

Reported quantities by phase

Select a point for its calculation examples
  1. Daily, fasted AM
    300 mcg
    Reports cluster around 250-500 mcg once daily fasted; some lower to about 175 mcg if headaches occur. Add extra BAC water (2-3 mL per 5 mg vial) to avoid gelling.

Vial-aware arithmetic

Reconstitution examples, up to 3 mL

Choose the vial quantity and BAC water first. The diagram and results below update for the selected 300 mcg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.

Vial quantity

Choose the quantity printed on the vial.

BAC water added

Use 1, 2 or 3 mL, or enter a custom volume up to 3 mL.

Open the full reverse calculator
Three millilitre research vial, diluent vial and capped U-100 syringe on an ink-blue surface
One small vial, one measured diluent volume and one U-100 scale. The arithmetic connects all three.
BAC water selected
3 mL

Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.

1 mL BAC
6 units

resulting U-100 draw

Concentration
5 mg/mL
BAC added
1 mL
2 mL BAC
12 units

resulting U-100 draw

Concentration
2.5 mg/mL
BAC added
2 mL

Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Human StudyOral and intravenous in early studiesStudy-specific; no quantitative regimen recovered
Adults with obesity enrolled in clinical development studies

Oral and intravenous research formulations were evaluated across early studies

The studies did not establish a subcutaneous research-vial regimen for routine use.

View source
Community GuideSubcutaneous in guideDaily
Third-party educational schedule for a 2 mg research vial

300 mcg daily in weeks 1-4 followed by 500 mcg daily in weeks 5-12

This is a community subcutaneous convention, not the oral or intravenous regimen used in the human development programme.

View source
Community GuideSubcutaneousOnce daily, fasted AM
authenticated research-forum (Peppys) reports

Subcutaneous reports cluster around 250-500 mcg once daily, taken fasted in the morning (some lower to about 175 mcg when headaches occur); dosing is described in micrograms rather than milligrams, and gelling or cloudiness is managed by adding extra bacteriostatic water, roughly 2-3 mL per 5 mg vial

Forum provenance from an authenticated archive with usernames omitted. Reports agree the injectable dose sits in the microgram range and that onset is slow, needing 8-12 weeks to judge; the subcutaneous route is kept separate from oral troche and topical cream forms rather than interconverted.

View source

Evidence summary

The human development programme does not support the confident dosing schedules commonly repeated by commercial protocol sites.

Protocol status

This page documents the evidence gap rather than presenting an unsupported injectable schedule.

Online research community archive check

The reviewed archive supplied handling discussion, not an administration schedule: it describes AOD-9604 as aggregation-prone, proposes solution pH 4-6 and low concentration, and says bacteriostatic-saline compatibility is unknown (raw/expert-posts/ep-lets-stick-together-aggregation.md:244-264, :362-368). These formulation claims do not validate the third-party injection schedule above.

Community provenance (Peppys)

An authenticated research-forum archive records subcutaneous AOD-9604 clustering around 250-500 mcg once daily, taken fasted in the morning, with a few reports lowering to about 175 mcg when headaches appear. The dominant technical theme is anti-gelling: members add extra bacteriostatic water, roughly 2-3 mL per 5 mg vial, and prefill and refrigerate to stop the solution clouding or gelling. Reports agree the dose belongs in the microgram range, that onset is slow at 8-12 weeks, and that the injectable route stays separate from oral troche and topical cream forms rather than being interconverted. Usernames are omitted and the planner above reproduces the arithmetic of the reported quantities rather than validating them.

Warnings and contraindications

AOD-9604 is not an authorised medicine for weight management.
Commercial protocol claims exceed the conclusions supported by controlled human evidence.
Organised research bench with labelled storage tray, vial rack, notebook and thermometer
A clean workspace supports traceability. It does not establish sterility.

Shared across protocols

Supplies and general handling

Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.

Research vial

Select the labelled vial quantity used in the calculation.

View Peppys vial

Bacteriostatic water

Use only a diluent appropriate to the research method and formulation.

View Peppys BAC water

U-100 measuring syringe

Use a new sterile device for every entry. Source locally.

Source locally

Wipes and sharps container

Plan clean handling and immediate sharps disposal. Source locally.

Source locally

Storage follows the label

Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.

Use sterile equipment once

CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.

Stability is formulation-specific

Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.